Review · United States
Semax
Reviewed on
Approval and product status
Registered in Russia; no FDA-approved U.S. product or final 503A listing was identified as reviewed August 30, 2026
Semax free base and Semax acetate are distinct chemical forms. A product name does not show which form it contains or whether it matches the material studied. N-acetyl Semax amidate is a different modified substance, not a Semax alias.
What was measured in people?
- Health results · Limited
- Small and limited human studies do not establish the focus, memory, or treatment claims made online.
- Body changes · Limited
- FDA found no human pharmacokinetic studies, which measure how the body handles a drug. Human exposure and effects are not well characterized.
A change in a hormone or body signal does not by itself prove a health benefit.
Important limits
This tool is not an independent medical review. It does not recommend treatment.
This guide does not provide dosing, route, sourcing, product-selection, or treatment advice. A Russian registration or an advisory vote does not prove U.S. approval, product quality, or personal safety.
Still unknown: Studies do not show that Semax improves focus, memory, attention, or daily function. A 24-person study measured links on brain scans. It did not test thinking or daily function. FDA found no human study of how the body handles Semax. It found no safety data for use under the skin. Most reports gave few safety details. FDA warned about impurities, peptide clumps, immune reactions, and possible bleeding. No record shows an online product matches the form or study material.
This record cannot check a package, seller, batch, or personal treatment. It does not provide sport clearance.
Approval fact checks
“Semax is FDA-approved in the United States.”
Misleading. FDA says Semax free base and Semax acetate are not components of an FDA-approved drug. A drug registered in Russia does not create U.S. approval.
Applies to: United States approval status as reviewed August 30, 2026.
“The advisory vote added Semax to the 503A list or approved it.”
Misleading. RAPS reported an 8-5 advisory-committee vote in favor of adding Semax to the 503A list. FDA says advisory recommendations are non-binding, and the briefing says FDA had not made its final determination. No final FDA rule or listing was identified in this review.
Applies to: The July 2026 advisory vote and U.S. 503A status as reviewed August 30, 2026; a recommendation is not a final FDA decision or drug approval.
Cited sources (5)
- Regulatory Affairs Professionals Society: FDA advisory committee backs two more peptides, rejects one for compounding list
- U.S. Food and Drug Administration: July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting
- U.S. Food and Drug Administration: FDA evaluation of Semax-related bulk drug substances
- U.S. Food and Drug Administration: Bulk drug substances used in compounding under section 503A
- Electronic Code of Federal Regulations: 21 CFR 216.23 bulk drug substances list
Products in this review
These are selected records, not every product or form.
No product label record is included here. That is not a separate approval decision. Read the status and sources above.
What the research shows
FDA reviewed Semax for reduced blood flow to the brain, migraine, and severe facial pain. They found too little proof for all three uses. A 1997 stroke study compared 30 Semax-treated people with 80 people who received standard care. Its abstract did not say how large the change was. A 2018 stroke study followed 110 people, but its abstract did not show random group assignment or blinding. The 12-person migraine and 25-person facial-pain groups had no control group or blinding.
Read all Semax fact checksSources used in this review
A source may support some statements, not all of them. Use the links above or this review to see what each source supports.
Show 10 sources
- FDA evaluation of Semax-related bulk drug substances
U.S. Food and Drug Administration · FDA review · 2026
Source accessed
- July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting
U.S. Food and Drug Administration · Regulatory · 2026
Source accessed
- Bulk drug substances used in compounding under section 503A
U.S. Food and Drug Administration · Regulatory · 2026
Source accessed
- 21 CFR 216.23 bulk drug substances list
Electronic Code of Federal Regulations · Regulatory · 2026
Source accessed
- FDA substance record for Semax free base
U.S. Food and Drug Administration · Reference · 2026
Source accessed
- The efficacy of Semax in the treatment of patients at different stages of ischemic stroke
PubMed · Human clinical study · 2018
Source accessed
- Effectiveness of Semax in acute period of hemispheric ischemic stroke
PubMed · Human clinical study · 1997
Source accessed
- Resting brain-scan study in 24 healthy adults
PubMed · Frontiers in Human Neuroscience · Human pharmacology · 2018
Source accessed
- N-acetyl Semax amidate identity record
PubChem · Reference · 2026
Source accessed
- FDA advisory committee backs two more peptides, rejects one for compounding list
Regulatory Affairs Professionals Society · Reference · 2026
Source accessed